Loading…
DRTS
Alpha Tau Medical Ltd.
NASDAQ· Healthcare· Biotechnology
$14.64-1.15%
Key metrics
- Market cap
- $1.35B
- P/E
- —
- Forward P/E
- —
- P/B
- 30.7x
- Dividend yield
- —
- EPS
- -$1.04
- ROE
- -141.68%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.19
- 52-week high
- $15.10
- 52-week low
- $3.35
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- 121
- Jerusalem, Israel
Company description provided by Yahoo Finance.